Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy-Reference-Cited by-同舟云学术

Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy

Published:2011-04 Issue:4 Volume:22 Page:979-984
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Khimani N.B.,Ng A.K.,Chen Y.H.,Catalano P.,Silver B.,Mauch P.M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/4/979/572404/mdq548.pdf

Reference16 articles.

1. Statistical Report. Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2005;CBTRUS,2009

2. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Oncology Group (RTOG): RTOG 8315;Nelson;Int J Radiat Oncol Biol Phys,1992

3. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma;DeAngelis;J Clin Oncol,2002

4. Long-term survival in primary CNS lymphoma;Abrey;J Clin Oncol,1998

5. Treatment for primary CNS lymphoma: the next step;Abrey;J Clin Oncol,2000

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma;CNS Oncology;2024-05-09

2. Radiotherapeutic palliation of lymphoma;Palliative Radiation Oncology;2024

3. Prevention and management of secondary central nervous system lymphoma;Haematologica;2022-11-17

4. Revisiting the Concept of Recurrence of Primary Central Nervous System Lymphomas After Complete Response to Methotrexate-Based Therapy: Periventricular Reseeding as the Predominant Mechanism of Recurrence;Advances in Radiation Oncology;2022-07

5. Efficacy and toxicity with radiation field designs and concurrent temozolomide for CNS lymphoma;Neuro-Oncology Practice;2022-06-22